BCL2 and acute myeloid leukemia: The BCL2 inhibitor venetoclax (VEN) has been successfully utilized in the treatment of various hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [14, 15].